User login
DENVER – A limited number of safe and effective topical medications are currently available to treat chronic papulopustular (inflammatory) rosacea. In a video interview at the annual meeting of the American Academy of Dermatology, Dr. Linda Stein Gold highlighted results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of the disorder. Both studies of ivermectin 1% cream met their co-primary efficacy endpoints of treatment success as defined by the Investigator’s Global Assessment (IGA) rating of clear skin and change in inflammatory lesion count.
DENVER – A limited number of safe and effective topical medications are currently available to treat chronic papulopustular (inflammatory) rosacea. In a video interview at the annual meeting of the American Academy of Dermatology, Dr. Linda Stein Gold highlighted results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of the disorder. Both studies of ivermectin 1% cream met their co-primary efficacy endpoints of treatment success as defined by the Investigator’s Global Assessment (IGA) rating of clear skin and change in inflammatory lesion count.
DENVER – A limited number of safe and effective topical medications are currently available to treat chronic papulopustular (inflammatory) rosacea. In a video interview at the annual meeting of the American Academy of Dermatology, Dr. Linda Stein Gold highlighted results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of the disorder. Both studies of ivermectin 1% cream met their co-primary efficacy endpoints of treatment success as defined by the Investigator’s Global Assessment (IGA) rating of clear skin and change in inflammatory lesion count.
AT THE AAD ANNUAL MEETING
